GWM
SNDX icon

Geneos Wealth Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Geneos Wealth Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-75
Closed -$921 – 3213
2025
Q1 		$921 Hold
75
– – ﹤0.01% 2952
2024
Q4 		$992 Buy
75
+1
+1% +$17 ﹤0.01% 2769
2024
Q3 		$1.43K Buy
+74
New +$1.53K ﹤0.01% 2373
2020
Q2 		– Sell
-470
Closed -$4K – 2617
2020
Q1 		$4K Buy
+470
New +$4.41K ﹤0.01% 2123

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geneos Wealth Management's SNDX Position: Q2 2025 in Review

Geneos Wealth Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 75 shares — an estimated $921 sold.

Geneos Wealth Management first reported a position in SNDX in Q1 2020 and held it in 4 quarters. The position peaked at $4K in Q1 2020. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Geneos Wealth Management reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 75 Syndax Pharmaceuticals shares in Q2 2025, an estimated $921.
  • Geneos Wealth Management first reported a position in Syndax Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Geneos Wealth Management's Syndax Pharmaceuticals position peaked at $4K in Q1 2020.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Geneos Wealth Management's 13F filing for Q2 2025, filed 18 Aug 2025.